Yoshito Komatsu
Hokkaido University
338 Papers
1.1K Citations
Yoshito Komatsu is an academic researcher from Hokkaido University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 36, co-authored 278 publications.
Chat about Author
Papers
A Survey Using a Terminal Care Attitude Scale Intended for Oncologists and Palliative Care Staff
Masayoshi Kumai,Shintaro Kato,Ryo Koyanagi,Kenkichi Tsuruga,Yoichi M. Ito,Takehiro Yamada,Yoh Takekuma,Mitsuru Sugawara,T. Kawamoto,Yoshito Komatsu +9 more
TL;DR: Frommelt Attitude Toward Care Of Dying Scale Form B (FATCOD B-J) as mentioned in this paper ) is a variant of the ATCOD-B-J.
Endoscopic clip application for closure of esophageal perforations caused by EMR.
Yuichi Shimizu,Mototsugu Kato,Junji Yamamoto,Souichi Nakagawa,Yoshito Komatsu,Hiroyuki Tsukagoshi,Masahiro Fujita,Masao Hosokawa,Masahiro Asaka +8 more
TL;DR: When esophageal perforation caused by EMR is immediately recognized, endoscopic application of metallic clips is appropriate therapy, however, patients must be carefully monitored for the development of generalized mediastinitis.
P31-9 A retrospective study of elderly and non-elderly patients with metastatic pancreatic cancer treated with GEM+nab-PTX therapy
T. Kawamoto,Kazuaki Harada,Takashi Yamamura,Ryosuke Watanabe,Takeaki Nakamura,Satoshi Yuki,Masaki Kuwatani,Yoshito Komatsu,Naoya Sakamoto +8 more
TL;DR: This retrospective study examines the efficacy and safety of gemcitabine plus nab-paclitaxel therapy in elderly and non-elderly patients with metastatic pancreatic cancer, addressing concerns about chemotherapy eligibility in elderly patients with reduced performance status and organ function.
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer
Hideyuki Hayashi,Takashi Kohno,Hideki Ueno,Nobuyoshi Hiraoka,Shunsuke Kondo,Motonobu Saito,Yoko Shimada,Hitoshi Ichikawa,Mamoru Kato,Tatsuhiro Shibata,Chigusa Morizane,Yasunari Sakamoto,Kazuaki Shimada,Yoshito Komatsu,Naoya Sakamoto,Takuji Okusaka +15 more
TL;DR: The number of mutated driver genes assessed using a targeted deep sequencing assay was a promising prognostic biomarker for pancreatic cancer, and patients with fewer mutations among the four driver genes tended to have a better outcome.
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
Yoshiaki Nakamura,Hiroya Taniguchi,Masafumi Ikeda,Hideaki Bando,Ken Kato,Chigusa Morizane,Taito Esaki,Yoshito Komatsu,Yasuyuki Kawamoto,Naoki Takahashi,Makoto Ueno,Yoshinori Kagawa,Tomohiro Nishina,Takeshi Kato,Yoshiyuki Yamamoto,Junji Furuse,Tadamichi Denda,Hisato Kawakami,Eiji Oki,Takako Nakajima,Naohiro Nishida,Kensei Yamaguchi,Hisateru Yasui,Masahiro Goto,Nobuhisa Matsuhashi,Koushiro Ohtsubo,Kentaro Yamazaki,Akihito Tsuji,Wataru Okamoto,Katsuya Tsuchihara,Takeharu Yamanaka,Izumi Miki,Yasutoshi Sakamoto,Hiroko Ichiki,Masayuki Hata,Riu Yamashita,Atsushi Ohtsu,Justin I. Odegaard,Takayuki Yoshino +38 more
TL;DR: An observational study on a large cohort of patients with gastrointestinal cancer demonstrates the utility of ctDNA analysis for accelerating the enrollment of patients in clinical trials with no accompanying deterioration in treatment efficacy.